Wim Tiest Email & Phone Number

Geel, Be

Connected-Pathology aka C-Path is a brand new full digital pathology service provider bridging preclinical, clinical and hospital applications, with a strong focus on optimization and enhancement of workflows by using AI. My role is to develop and enable digital tools across the workflow.

Diepenbeek, Limburg, Be

As CTO, driving technological and digital innovations in in-vivo, in-vitro, imaging and pathology services.

Niel, Be

Active role in leading the company through the series A program and into the next investment round* As head of preclinical research (2017) prioritising new research avenues and external collaborations. * As head of strategy and project management (2018) rebuilding the business plan for the next 5 years.* As Strategy lead and external advisor (2019) providing insight on key strategic topics.Assignment through OneCo

Ghent, Flemish Region, Be

Elected Board member of Flanders.Bio, on a 4 year mandate actively supporting one of the strongest European Health, Agro and Life Science clusters to become even stronger and more relevant for its members. Closely involved with the "TEST" strategic objective of the cluster revolving around clinical data generation.

I've founded and am managing a new company called OneCo that delivers consulting services in science and management, and develops simple but efficient processes and tools to enable change in organisations.OneCo is currently reshaping its activities to embrace the combination of artificial intelligence and industry experience into a new wave of exciting projects and solutions. Visit us at www.oneco.be.

Brentford, Middlesex, Gb

ACHIEVEMENTS:• Realization of R&D deal synergies.• Organization design and restructuring with reduction around 15% from a former 4000 heads and 1000 contractors.• Integration of processes and IT tools• Footprint consolidation in the US with site creation (Rockville) and closures (Laval, Hamilton, Cambridge and RTP)• Data Disposition of electronic and paper records with complex separation requirements for anti-trust and IP.• Drove a Change Management program• Took direct lead for Amsterdam site transition.• Managed 100mio £ integration budgetKEY EXPERIENCE:• All aspects of a pre- and post-merger integration program.• Starting and closing an R&D site.• Restructuring including org design, appointment and selection and redundancy.• Post-merger data transfers with complex separation requirements.• Work council consultation process• Communications of good and bad news.• Change management as a tool to rebuild teams• Setting up and motivating a highly agile integration team and maintaining under high turn-over.

Brentford, Middlesex, Gb

ACHIEVEMENTS:• Co-designed the initial fully integrated R&D Unit and planned commercial stage Business Unit and its governance.• Delivered with the team the 2 biggest ever phase III adjuvant trials in Melanoma and NSCLC. Generated with MAGE-A3 conclusive but negative results. Achieved full “readiness to file” for both product and diagnostic.• Build and lead a portfolio of phase I-II follow-on assets.• Dismantled the Unit by end 2014.• Grew a team of expert project leaders, portfolio managers and business operation staff. Enabled many after during and after the program to get on senior role in GSK.• Successfully managed operations, budget and resources of a program employing at peak 500 FTE and running at 80mio£ per year.• Preparation and presentation of strategic papers including the business case covering the expected multi-billion expansion post-MAGE-A3.• Took over the overall Companion Diagnostic program in 2014.KEY EXPERIENCE:• Repeated exposure to GSK corporate leadership (CFO, CEO, Board) and external experts defending program or providing updates.• Managing both growth and ramp-down phase of a big R&D program and associated people management.• Active contribution during all steps and events of the MAGE-A3 program from discovery to phase III and from research to commercial.• Deep understanding of immunology, vaccine development, cancer programs, smoking cessation, immunotherapy and companion diagnostic development.• Talent acquisition and enabling growth • Line management of a team of 40 internal and external associates.• Enterprise thinking as part of the unit’s executive team.• Passion for science.• Communication skills delivering several town hall and broadcasted presentations.

Brentford, Middlesex, Gb

• Lead several prophylactic and therapeutic vaccine projects with internal and external partners to reach decision points:o RSV as technical leado Lymerix and Lyme Europeo HPV E7 Cervical cancero GnRH, P703, P501 in Prostate cancero Her2Neu in Breast cancer• Lead MAGE-A3 project to reach phase II results allowing the decision to move to late stage development.• Development of PM enterprise tools

Brentford, Middlesex, Gb

• Set up and head the first Physicochemistry Release Assay Development Lab in R&D• Developed several adjuvant system assay methods in complex matrices (AlOH, emulsions, liposomes, MPL, QS21, CpG) that to date are still used as standard release assays in QC• Introduced new techniques in HPLC and detection modes, and perfected gel electrophoresis introducing pre-cast gels, imaging and capillary electrophoresis. • Hired and trained lab technicians that are still references in Vaccines in the fields of HPLC and gel electrophoresis.

Master Of Artificial Intelligence - Option Ecs, Artificial Intelligence

Master'S Degree, Biotechnology

Latin-Greek

Education record